Safety and tolerability of psilocybin-assisted physiotherapy in healthy volunteers

Single-group feasibility pilot in healthy volunteers using a Williams design: each participant receives three oral psilocybin doses (cohort A: 5,10,15 mg; cohort B: 10,15,20 mg) in sessions at least one week apart; doses are randomly ordered.

Primary assessments include physiotherapist-prescribed movement tasks (adapted from the DEMMI and Physio4FMD), hourly vital signs up to 5 hours post-dose, resting-state fMRI (baseline and after second dose), adverse-event monitoring with debrief and next-day phone follow-up, and qualitative interviews after final dose.